Determination of Acute Encephalopathy Predictors in Patients With COVID-19

Summary

The SARS-CoV-2 infection was detected in December 2019 in Wuhan City, China. The infection affects all age groups, although childhood is the lowest proportion of those affected.

The main clinical manifestations that require hospitalization of infected patients are SARS pneumonia, which may require treatment in the intensive care unit (27%) and its progression into acute respiratory distress syndrome (67%) with life-threatening conditions in almost 25% of patients diagnosed with "SARS-CoV-2 infection".

Nervous system damage with SARS-CoV-2 infection has been practically not investigated, but neurological disorders have been reported in 36% of these patients.

Finally, the mortality rate associated with the new virus is high in patients who require treatment in intensive care units (62% of cases).

Therefore, we are conducting a prospective study to identify acute encephalopathy predictors in patients with COVID-19.

Conditions

• Encephalopathy
• COVID

Interventions

DIAGNOSTIC_TEST

CT-scan

chest CT-scan

DIAGNOSTIC_TEST

EEG

Electroencephalography

DIAGNOSTIC_TEST

EP

Evoked potential

DIAGNOSTIC_TEST

Pulse oximetry

Pulse oximetry

DIAGNOSTIC_TEST

Blood tests

Blood tests

Sponsors & Collaborators

• State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia

  lead OTHER

Principal Investigators

• Oleg I Vinogradov, MD, PhD · N.I. Pirogov National Medical and Surgical Center

Study Design

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

60 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-05-22

Primary Completion

2020-07-22

Completion

2020-10-29

Countries

• Russia

Study Locations